ImmunoVaccine Completes Scale-Up of VacciMax
ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), has successfully scaled up the manufacturing process for its vaccine platform, VacciMax.
ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), has successfully scaled up the manufacturing process for its vaccine platform, VacciMax. This work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications. The manufacturing development was performed at Dalton Pharma Services, a Health Canada and GMP compliant pharmaceutical manufacturing and development company. The results show that IVT’s vaccine delivery platform can be produced on a commercial scale.
VacciMax is a vaccine-enhancement platform comprising a special emulsion of liposomes, antigens, adjuvants, and oil. The ability to scale-up, under GMP, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
